AI Article Synopsis
- * A case study is presented involving a 62-year-old man with immune-mediated TTP (iTTP) that developed over three years, including symptoms like low platelet count, recurrent strokes, and valve clots.
- * The report suggests a potential link between the use of adalimumab, a TNFα inhibitor, and the onset of iTTP, while also highlighting the need to recognize atypical manifestations of the disease due to its complex history and comorbid health issues in the patient.
Article Abstract
Prompt recognition and treatment for thrombotic thrombocytopenic purpura (TTP) are critical to prevent the irreversible manifestations of this rare and quickly fatal hematologic disorder. Untreated TTP is typically a rapid-onset disease with mortality exceeding 90% within days in the absence of appropriate treatment. In the current report, we describe a case of immune-mediated TTP (iTTP) in a 62-year-old man manifesting as longstanding thrombocytopenia, recurrent cardioembolic strokes, and valvular thrombogenesis over a period of 3 years. We provide correlative evidence to support the potential contribution of adalimumab, a TNFα inhibitor, to the development of iTTP. We offer several educational insights regarding the identification of atypical presentations of iTTP owing to the longstanding disease course and numerous clinical comorbidities seen in this patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507438 | PMC |
| http://dx.doi.org/10.1002/ccr3.4850 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!